Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11

Core Viewpoint - Codexis, Inc. will report its financial results for Q4 and fiscal year 2025 on March 11, 2026, and will host a conference call to discuss these results and provide a business update [1]. Company Overview - Codexis is a leading provider of enzymatic solutions aimed at efficient and scalable manufacturing of complex therapeutics, utilizing its proprietary CodeEvolver® technology platform [3]. - The company is developing the ECO Synthesis® manufacturing platform to facilitate the scaled manufacture of RNAi therapeutics through an enzymatic route [3]. - Codexis' enzymes are designed to address challenges in small molecule pharmaceuticals manufacturing and nucleic acid synthesis, offering benefits such as higher yields, reduced energy usage, and improved efficiency [3].